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Traumeel
w S (Traumeel), a mixture of highly diluted (10
21–10
29) extracts from medicinal plants and
minerals is widely used in humans to relieve trauma, inﬂammation and degenerative processes.
However, little is known about its possible effects on the behavior of immune cells. The effects of
Traumeel were examined invitro on the ability of resting and PHA-, PMA- or TNF-a-activated human
T cells, monocytes, and gut epithelial cells to secrete the prototypic pro-inﬂammatory mediators IL-1b,
TNF-a and IL-8 over a period of 24–72h. Traumeel inhibited the secretion of all three agents in
resting, as well as activated immune cells. IL-b secretion was reduced by up to 70% in both resting and
activated cells; TNF-a secretion was reduced by up to 65 and 54%, respectively, and IL-8 secretion was
reduced by 50% in both resting and activated cells (P , 0:01 for all cells). Interestingly, the effect
appeared to be inversely dose-related; maximal inhibition (usually 30–60% inhibition; P , 0:01) was
seen with dilutions of 10
23–10
26 of the Traumeel stock material. This ﬁnding suggests that Traumeel
doesnot inhibit immune cells functionsby exerting a toxiceffect. Indeed, Traumeel did notaffect T cell
and monocyte proliferation. Although additional studies are needed to clarify the mode of action of
Traumeel and to demonstrate causative relationship between the inhibition of cytokine/chemokine
secretion in cell culture and the reported clinical effects of the preparation, our in vitro results offer a
mechanism for the anti-inﬂammatory effects of Traumeel observed in clinical use.
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INTRODUCTION
Traumeel
w S is a widely used medication containing a
mixture of highly diluted (10
21–10
29 from mother
solution) extracts of medicinal plants and minerals. It has
been found beneﬁcial to humans suffering from a wide
spectrum of pathological conditions, including trauma,
inﬂammation and degenerative processes (Zenner and
Metelmann, 1992; Zenner and Weiser, 1997; Arora et al.,
2000; Oberbaum et al., 2001). However, Traumeel
includes only minute doses of its medicinal components.
For example, the concentration of Mercury in Traumeel
is lower than that allowed in drinking water in Germany.
Such effects have made Traumeel one of the most
popular alternative medications in Germany, where it is
also used by conventional physicians (primarily ortho-
pedists). A recent study showed the beneﬁcial effect
of Traumeel on chemotherapy-induced stomatitis in
children undergoing bone marrow transplantations
(Oberbaum et al., 2001). Chemotherapy-induced stoma-
titis is one of the most severe side effects of
chemotherapy; it has no effective treatment and often
limits the intensity of chemotherapy (Wilkes, 1998).
However, despite the long use, popularity (Traumeel is
one of the most popular alternative medicines in Germany,
used also by conventional physicians) and good efﬁcacy of
Traumeel in awide range ofindications, its mode of action
has been insufﬁciently studied. The current work analyzed
the effects of Traumeel on human leukocyte function
in vitro. Speciﬁcally, the effects of Traumeel were studied
on T cell activation and on T cell, monocyte, endothelial
cells and gut epithelial cell secretion of the major pro-
inﬂammatory cytokines IL-1b, TNF-a and IL-8 (Feldman
et al., 2001; Apte and Voronov, 2002; Strieter, 2002).
IL-1b was chosen, as it is a versatile and pivotal pro-
inﬂammatory mediator. TNF-a is involved, along with
IL-1b, in various aspects and reactions of the immune
system, as well as in autoimmune and acute inﬂammatory
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chemokine involved in the activation and recruitment of
leukocytes, predominantly neutrophils, from blood vessels
to extravascular sites of inﬂammation.
MATERIAL AND METHODS
Materials
Traumeel was obtained, free of charge, from Biologische
Heilmittel Heel GmbH (Baden-Baden, Germany).
Traumeel
w S is supplied in glass ampoules prepared for
injection, each containing 2.2ml of the medication.
The active ingredients of Traumeel are prepared in
accordancewith the German Homeopathic Pharmacopoeia.
The following reagents and chemicals were used: human
recombinant TNF-a, phorbol myristate acetate (PMA),
BSA, heparin (Sigma; St. Louis, MO, USA), RPMI 1640
medium (Gibco BRL), M199 medium, HEPES buffer,
antibiotics, heat-inactivated fetal calf serum (FCS),
glutamine,sodiumpyruvate (Kibbutz Beit-Haemek, Israel).
Cells and Cell Culture
T cells from healthy human peripheral blood (PBL) were
isolated on Ficoll gradients, washed, resuspended in PBS
containing 3% heat-inactivated FCS, and incubated
(45min, 378C, 7% CO2-humidiﬁed atmosphere) on
nylon–wool columns (NovaMed; Jerusalem, Israel), as
described (Franitza et al., 2000; Ariel et al., 2002). Non-
adherent cells were eluted and washed, and platelets were
removed by centrifugation (700rpm, 15min, 188C).
Residual monocytes were removed by incubating
(2h, 378C) the cells on tissue culture plates, and collecting
the non-adherent cells. The PBL thus obtained contained
.95% CD3
þ cells, as determined by FACScan analysis.
Where indicated, an in vitro co-culture system was used
involving two human cell lines—Jurkat (T cells) and the
monocytic cell line THP-1. PBLs, JurkatT cells and THP-1
monocyteswereculturedinRPMI1640medium(10%heat-
inactivated FCS, 1% antibiotics, 1% glutamine and 1%
pyruvate) in 75-cm
2 tissue culture ﬂasks (Falcon) singly.
Freshly isolated human umbilical vein endothelial cells
(HUVEC) were cultured in M199 medium containing
20% FCS, 1% glutamine, 0.1% gentamicin, 1% HEPES,
0.1% heparin and 0.1% EGF. Human colonic epithelial
line cells, designated HT-29, were cultured in McCoy’s
medium, supplemented with 10% heat-inactivated FCS,
1% glutamine and 1% antibiotics, as previously described
(Chowers et al., 2001). HUVEC and HT-29 cells were
grown in 24-well tissue culture plates (Corning Inc.,
Corning, NY).
Determination of IL-1b, TNF-a and IL-8 by ELISA
To measure cytokine secretion, HT-29 and HUVEC cells
were seeded onto 24-well plates and grown until conﬂuent
monolayers were formed. To determine the IL-1b and
IL-8 secretions, the indicated cells were analyzed in two
different series of experiments: (1) cells were incubated in
fresh medium containing various dilutions of Traumeel
(usually 10
21–10
27) for 24, 48 or 72h; (2) the cells were
treated with Traumeel (24h) before TNF-a-activation
(100ng/ml; 24h). Alternatively, the cells were incubated
with their respective activator before exposure to
Traumeel. PBLs were seeded onto the 24-well plates
(2 £ 10
6cells/ml/well) and stimulated with PHA
(1mg/ml; 24h) under the same conditions described
previously. To measure cytokine secretion by the two cell
lines, the Jurkat and THP-1 cells were mixed (2 £ 10
6
and 2.5 £ 10
5cells/ml, respectively; 1ml/well), and
treated for 48h with PHA (4mg/ml) and PMA
(50ng/ml) before exposing the cells to Traumeel (24h).
In a separate series of experiments, the cells were
preincubated with Traumeel (24h) and subsequently
treated with the activators. Control cells were incubated
only with Traumeel (24 or 72h). Following the different
treatments, the supernatants were collected, cleared by
centrifugation and stored at 2208C until evaluation by
ELISA. All cytokine measurements were carried out using
conventional ELISA kits and reagents (BioSource
International, Inc., USA), according to the manufacturer’s
instructions (Chowers et al., 2001).
Statistical Analysis
The results shown are from one representative experiment
out of a minimum of three identical experiments that
yielded comparable results or, when indicated, the average
of identical experiments. The data are expressed as means
(^SD) of cytokine/chemokine content in supernatants of
triplicate or quadruplicate wells. Statistical analysis of the
differences between the means of the different groups
within a given experiment was evaluated using the paired
Student’s t-test.
RESULTS
Effects of Traumeel on IL-1b Secretion from Resting,
Co-cultured Jurkat and THP-1 Cells
Different concentrations of Traumeel were added to
co-cultures of Jurkat and THP-1 cells which were
maintained under tissue culture conditions for either 24
or 72h. IL-b secretion was measured by ELISA. Note as
shown in Fig. 1 and in additional ﬁgures in which the
secretion of other cytokines was tested, that the
spontaneous release of TNF-a is indicated as the secreted
protein in the absence of Traumeel. The results, shown in
Fig. 1A, indicate that while there was no effect on IL-1b
secretion when cells were incubated with Traumeel for
24h, when the co-cultured cells were treated with
Traumeel for 72h, a dose-dependent effect was obtained.
Interestingly, Traumeel in a dilution of 1:10 markedly
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cells and monocytes (from 60 to 24pg/ml; P , 0:05);
further dilutions of up to 10
27 exerted an inversely dose–
response inhibition of the basal levels of IL-1b secretion,




Further, cells of both types were exposed for 24h to
different dilutions of Traumeel, either before or after their
activation with PHA and PMA (for 48h). The results
indicate that Traumeel inhibited IL-1b secretion when
used either before or after PHA activation (Fig. 1B).
However, whereas pretreatment of cells with Traumeel
led to an inverse bell-shaped dose–response curve
reaching the maximal inhibition at 10
25 dilution, late
exposure of the activated cells to Traumeel yielded a
reversed dose–response curve, reaching a maximal
inhibition of IL-1b secretion at 10
22 dilution (from
1100pg/ml at baseline to 330pg/ml). These pattern of
dose-dependency effects of Traumeel also implies that
this medication do not affect T cell function via
cytotoxicity. In fact, in a separate set of studies, we
could not detect any effect on T cell viability and
proliferation, even when the cells were exposed to
Traumeel for 3 days (not shown).
Effects of Traumeel on TNF-a Secretion from Jurkat
and THP-1 Cells
Non-activated immunocytes were incubated with different
concentrations of Traumeel for 24 and 72h. TNF-a
secretion was measured in the supernatants at the end of
the assay, using ELISA. The results, shown in Fig. 2A,
indicate that Traumeel signiﬁcantly inhibits TNF-a
secretion ðP , 0:01Þ when diluted to 10
23–10
27. Similar
to the effects on IL-1b, inhibition was more evident after
prolonged Traumeel incubation. Moreover, an inverse
dose–response pattern of inhibition of TNF-a secretion
was observed when the cells were incubated with
Traumeel for 72h (Fig. 2A).
The modulatory effects of Traumeel on PHA and
PMA-activated Jurkat and THP-1 cells were evaluated as
described in the legend to Fig. 1. The results, shown in
Fig. 2B, demonstrate a similar inhibition pattern of TNF-a
secretion by Traumeel, irrespective of whether the cells
FIGURE 1 Effects of Traumeel on IL-1b secretion from interacting, resting and PHA- and PMA-activated Jurkat and THP-1 cells. (A) The human
CD4
þ line of T cells and monocytes (THP-1) were co-cultured under tissue culture conditions and incubated with the indicated concentrations (serial
dilutions) of Traumeel for 24h (circles) and 72h (triangles). Each data point represents the mean (^SD) of triplicate wells. One experiment
representative of ﬁve. (B) Human T cell lines were either pre-exposed to Traumeel and subsequently activated with PHA and PMA for 48h (circles) or
activated with PHA and PMA for 48h, washed and exposed to Traumeel for an additional period of 24h (triangles). Each data point represents the mean
(^SD) of triplicate wells. One experiment representative of three.
ANTI-INFLAMMATORY EFFECTS OF TRAUMEEL 145FIGURE 2 Effects of Traumeel on TNF-a secretion from interacting, resting and PHA- and PMA-activated Jurkat and THP-1 cells (A, B) and from
activated PBL cells (C). (A) THP-1 and Jurkat cells were maintained under tissue culture conditions while exposed to the indicated serial dilutions of
Traumeel for 24h (circles) and 72h (triangles). Each data point represents the mean (^SD) of triplicate ELISAwells. One experiment representative of
four. (B) Human cells were either pre-exposed to Traumeel and subsequently activated with PHA and PMA for 48h (circles) or activated with PHA and
PMA for 48h, washed and exposed to Traumeel for an additional period of 48h (triangles). Each data point represents the mean (^SD) of triplicate
wells. One experiment representative of ﬁve. (C) Human PBL cells were either pre-exposed to Traumeel for 24h and subsequently activated with PHA
for 24h (circles) or activated with PHA for 24h, washed and exposed to Traumeel for an additional period of 24h (triangles). Each data point represents
the mean (^SD) of triplicate wells. One experiment representative of four.
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activators. Basal levels of TNF-a secretion were
signiﬁcantly lower ðP , 0:05Þ when cells were exposed
to Traumeel before activation. Under both conditions, the
inhibitory effect of Traumeel on TNF-a secretion was
evident at concentrations of 10
21–10
24 ðP , 0:01Þ:
However, at the higher dilutions of Traumeel, the level of
inhibition of TNF-a secretion gradually decreased until it
reached basal secretion levels.
Effects of Traumeel on TNF-a Secretion from Freshly
Isolated Human T Cells
The previous experiments indicate that Traumeel can
affect the secretion of IL-1b and TNF-a from Jurkat and
THP-1 human T cell lines. To examine whether Traumeel
can modulate TNF-a secretion from T cells isolated from
healthy human donors, such T cells were treated with
Traumeel (24h) shortly after their separation and
subsequently activated with PHA (24h), or vice versa.
The level of secreted TNF-a was measured by ELISA.
The results, shown in Fig. 2C, indicate an inhibition at
10
21–10
24 dilutions of Traumeel ðP , 0:05Þ: Similarly
to the effects observed with activated human T cell lines,
there was no inhibition at dilutions of 10
25–10
27.
Effects of Traumeel on IL-8 Secretion from
Non-activated and Activated HT-29 Cells
The effects of Traumeel on the secretion of IL-8 from the
monocytic cell line THP-1 was also investigated.
Figure 3A shows a reverse dose–response inhibition by
Traumeel, with a maximal inhibitory effect of 40–50%
ðP , 0:05Þ occurring at 10
24–10
25 dilutions.
FIGURE 3 Effects of Traumeel on IL-8 secretion from resting (A) and activated (B) HT-29 cells. (A) Cells from the human gut epithelial cell line,
HT-29, were incubated (24h) with the indicated concentrations of Traumeel and Il-8 secretion was measured using ELISA. Each data point represents
the mean (^SD) of triplicate wells. One experiment representative of three. (B) Cells were pre-incubated with Traumeel, and subsequently activated
with TNF-a for 24h (circles), or activated with TNF-a for 24h, and subsequently exposed to the indicated concentrations of Traumeel for 24h
(triangles). Each data point represents the mean (^SD) of triplicate wells. One experiment representative of four.
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TNF-a-activated THP-1 cells were studied. The results,
shown in Fig. 3B, indicate that irrespective of whether the
cells were ﬁrst exposed to Traumeel and subsequently
activated or vice versa, there was a gradual inhibition of
IL-8 secretion, reaching a maximal effect of 40–50%
inhibition ðP , 0:05Þ at dilutions of 10
25–10
27.
Effects of Traumeel on IL-1b Secretion from Human
Gut Epithelial Cells
The effects on IL-1b secretion by the human gut epithelial
cell line HT-29 by different dilutions of Traumeel (24 and
48h) were investigated. The results, shown in Fig. 4A,
indicate an inhibition of IL-1b secretion of 30–50% when
cells were exposed to Traumeel for 24 or 48h. Unlike the
gradual and consistent effect at low dilution (10
24–10
27)
on mobile immunocytes, inhibition of IL-1b secretion
from the non-activated epithelial cells was reduced at
higher dilutions.
Finally, the putative effect of Traumeel on the secretion
of IL-1b from TNF-a-activated HT-29 cells was
examined, assuming that such an activation may occur
in vivo during inﬂammation. At 1–10% dilutions, there
was signiﬁcant inhibition of IL-1b secretion (80%;
P , 0:01; Fig. 4B).
DISCUSSION
Traumeel has been on the market for approximately 80
years, and has a long record of use in millions of patients
(Zenner and Weiser, 1997; Arora et al., 2000). It has been
postulated that Traumeel has beneﬁcial anti-traumatic and
anti-inﬂammatory activities as indicated in a wide range
of cases (Lussignoli et al., 1999; Oberbaum et al., 2001).
However, in contrast to its wide clinical use, little is
known as to whether (and how) Traumeel affects immune
cell functions related to inﬂammation. This study reports
that the homeopathic remedy Traumeel, at dilutions of
10
21–10
27, inhibits, in a unique dose-dependent fashion,
the secretion of the pro-inﬂammatory cytokines IL-1b
TNF-a and the chemokine IL-8, from (mobile) human
leukocytes and (resident) gut epithelial cells in vitro.
Interestingly, Traumeel appears to negatively affect the
secretionofthetestedcytokineandchemokine,fromeither
FIGURE 4 Effects of Traumeel on IL-1b secretion from resting (A) and TNF-a-activated (B) HT-29 cells. (A) HT-29 cells were exposed to Traumeel
for 24h (circles) or 48h (triangles) prior to the measurement of IL-1b secretion. Each data point represents a mean (^SD) of triplicate wells.
One experiment representative of four. (B) Cells were activated with TNF-a (24h), and subsequently exposed to the indicated amounts of Traumeel.
Each data point represents the mean (^SD) of triplicate wells. One experiment representative of ﬁve.
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inversely dose–response pattern. This phenomenon was
observed in all the tested cell types or their combinations,
regardless of whether the cells were non-activated or
activated with PHA/PMA or TNF-a. In none of the
experiments did Traumeel increase the secretion of the
pro-inﬂammatory mediators, whether or not the cells were
activated by other means, implying that the medication
lacks any activating (or inﬂammatory) capacity. The
results support the characterization of Traumeel as an anti-
inﬂammatory medication.
The human cell types studied were chosen because they
represent either the mobile arm of the immune system in
the form of blood-borne T cells (freshly isolated or of the
Jurkat CD4
þ T cell line) and monocytes (THP-1 cell line),
or the ﬁrst line of immune defense of the gut-associated
immune system represented by the resident, non-mobile
gut epithelial cells (HT-29 cell line). In all cases, Traumeel
exerted comparable inhibitory effects on the secretion of
the pro-inﬂammatory mediators. It is noteworthy that the
apparent inhibitory concentrations of Traumeel, i.e. 10-3-
10-8, are similar to those active in vivo in stomatitis
(Oberbaum et al., 2001).
There is a great need for rigorous studies of the
actions of remedies such as Traumeel, which are
frequently used in the practice of complementary
medicine and homeopathy (Jonas et al., 2003). The
current investigation shows that Traumeel treatment
inﬂuences immune cell functions related to inﬂammation
in vitro. Inhibition of IL-1b, TNF-a and IL-8 secretion
from resting or (PHA-, PMA-, or TNF-a)-activated
immunocytes by Traumeel was clearly shown. However,
the results presented leave many questions unanswered,
e.g. the mode of action, and whether Traumeel affects
other facets of immune cell behavior during inﬂam-
mation such as proliferation, expression of activation-
related receptors, adhesion to other cells or to
components of blood vessel walls and extracellular
matrix. It is conceivable but unproven that Traumeel
interferes with speciﬁc intracellular signal transduction
pathways. Furthermore, Traumeel is a mixture of several
plant extracts and minerals and the contribution of each
ingredient, as well as possible synergistic effects of the
composition, needs further study.
As to the inversely dose-dependent effects, we can only
speculate that the optimal immuno-modulatory effect of
the mixture requires exact concentrations of the active
compounds. Hence, Traumeel at too high or too low
dilutions would fail to exert an inhibitory effect on
cytokine secretion. Be that as it may, it was noteworthy
that Traumeel did not show any activating effects even at
the higher concentrations 10
21–10
23. Be that as it may,
these results also imply that the above-mentioned effects
of Traummel are not due to toxic effect of the medication.
Indeed, in a separate set of studies, we could not detect
any effect of Traumeel on T cell and monocyte
proliferation (and viability), even if the cells were
exposed to the active concentration of the medication for
72h (not shown). Interestingly, we had previously found
that a naturally-occurring breakdown product of heparan
sulfate proteoglycan, which is generated in vivo by the
action of heparanase, also inhibited TNF-a secretion, but
not T-cell proliferation (Lider et al., 1995).
The mode of interaction with immune cells also would
need detailed investigation. It remains to be established
whether Traumeel interacts with speciﬁc cell surface rece-
ptors or penetrates the cell membranes. However, all such
theories, although testable, remain speculation at present.
The current results should challenge researchers to
study the indicated anti-activating and anti-inﬂammatory
potential of Traumeel, both in vitro and in vivo, in animal
models of inﬂammation. If such studies corroborate the
ﬁndings presented in the current work, this would be
strong support for the use of Traumeel and possibly of
related medications as conventional therapeutic modali-
ties administered to patients suffering from chronic or
acute inﬂammatory isorders.
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